The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
 
Grant Rauterkus
No Relationships to Disclose
 
Agreen Hadadi
No Relationships to Disclose
 
Reagan Barnett
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Caroline Weipert
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
 
Leylah Drusbosky
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Xin Gao
Consulting or Advisory Role - Bayer; Dendreon; Exelixis; Flare Therapeutics; Guardant Health
Research Funding - Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Merck (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Michael B. Lilly
Speakers' Bureau - Guardant Health
Research Funding - Bavarian Nordic (Inst); Bayer (Inst)
 
Alan Haruo Bryce
Honoraria - Astellas Pharma; Bayer
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)
 
Syed Arsalan Ahmed Naqvi
No Relationships to Disclose
 
Pedro C. Barata
Consulting or Advisory Role - Bayer; BMS; Caris Life Sciences; Clovis Oncology (Inst); Dendreon (Inst); Eisai; EMD Serono; Pfizer
Research Funding - Blue Earth Diagnostics (Inst)
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)